Basit öğe kaydını göster

dc.contributor.authorMalkan, Umit Yavuz
dc.contributor.authorGunes, Gursel
dc.contributor.authorIsik, Ayse
dc.contributor.authorEliacik, Eylem
dc.contributor.authorEtgul, Sezgin
dc.contributor.authorAslan, Tuncay
dc.contributor.authorBalaban, Muruvvet Seda
dc.contributor.authorHaznedaroglu, Ibrahim Celalettin
dc.contributor.authorDemiroglu, Haluk
dc.contributor.authorGoker, Hakan
dc.contributor.authorOzcebe, Osman Ilhami
dc.contributor.authorSayinalp, Nilgun
dc.contributor.authorAksu, Salih
dc.contributor.authorBuyukasik, Yahya
dc.contributor.authorMahallesi, Mutlukent
dc.date.accessioned2019-12-10T11:20:19Z
dc.date.available2019-12-10T11:20:19Z
dc.date.issued2015
dc.identifier.issn0001-5792
dc.identifier.urihttps://doi.org/10.1159/000369917
dc.identifier.urihttp://hdl.handle.net/11655/15308
dc.description.abstractThere are very few data about the relationship between acute myeloid leukemia (AML) prognosis and bone marrow recovery kinetics following chemotherapy. In this study, we aimed to assess the prognostic importance and clinical associations of neutrophil and platelet recovery rates and rebound thrombocytosis (RT) or neutrophilia (RN) in the post-chemotherapy period for newly diagnosed AML patients. De novo AML patients diagnosed between October 2002 and December 2013 were evaluated retrospectively. One hundred patients were suitable for inclusion. Cox regression analysis using need for reinduction chemotherapy as a stratification parameter revealed RT as the only parameter predictive of OS, with borderline statistical significance (p = 0.06, OR = 7; 95% CI 0.92-53), and it was the only parameter predictive of DFS (p = 0.024, OR = 10; 95% CI 1.3-75). In order to understand whether RT or RN was related to a better mar-row capacity or late consolidation, we considered neutrophil recovery time and platelet recovery time and nadir-first consolidation durations in all patients in the cohort. Both the marrow recovery duration and the time between marrow aplasia and first consolidation were shorter in RT and RN patients. To our knowledge, this is the first study to report a correlation between RT/RN and prognosis in AML. (C) 2015 S. Karger AG, Basel
dc.language.isoen
dc.publisherKarger
dc.relation.isversionof10.1159/000369917
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHematology
dc.titleRebound Thrombocytosis Following Induction Chemotherapy Is An Independent Predictor of A Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalActa Haematologica
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume134
dc.identifier.issue1
dc.identifier.startpage32
dc.identifier.endpage37
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster